Dependence of reversibility and progression of mouse neuronopathic Gaucher disease on acid β-glucosidase residual activity levels
- 17 March 2008
- journal article
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 94 (2), 190-203
- https://doi.org/10.1016/j.ymgme.2008.01.013
Abstract
No abstract availableKeywords
This publication has 52 references indexed in Scilit:
- Neuropathology provides clues to the pathophysiology of Gaucher diseaseMolecular Genetics and Metabolism, 2004
- Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)The Journal of Pediatrics, 2004
- Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: consensus recommendationsThe Journal of Pediatrics, 2004
- Phenotypic continuum in neuronopathic gaucher disease: an intermediate phenotype between type 2 and type 3The Journal of Pediatrics, 2003
- Agalsidase alfa – a preparation for enzyme replacement therapy in Anderson–Fabry diseaseExpert Opinion on Investigational Drugs, 2002
- β-Catenin Controls Hair Follicle Morphogenesis and Stem Cell Differentiation in the SkinCell, 2001
- Neuropathology of the Norrbottnian type of Gaucher diseaseActa Neuropathologica, 1984
- Abnormal accumulation of galactosylceramide in the kidney of twitcher mouseBiochemical and Biophysical Research Communications, 1983
- Enzymic effects of β-glucosidase destruction in mice changes in glucuronidase levelsBiochimica et Biophysica Acta (BBA) - General Subjects, 1979
- The Gaucher mouseBiochemical and Biophysical Research Communications, 1975